Industry
Rare Diseases market research
Hard-to-reach patient and specialist research for orphan drug developers.
HealthcareMarketResearch runs rare diseases market research for global leaders, challengers and investors. Our 5,000+ researchers include practising clinicians, procurement leaders, payers and former executives from the rare diseases industry.
Studies combine expert calls, qualitative interviews and quantitative surveys, so you can size the opportunity, understand stakeholders and plan go-to-market with confidence.
Topics we research
- Patient finding
- Centres of excellence
- Advocacy groups
- Pricing
Relevant services
At a glance
Rare Diseases market research at a glance
The audiences, methods and timelines a typical rare diseases study runs on.
- Audiences
- Rare Diseases specialists and clinicians, pharmacy and procurement leads, payers and HTA assessors, plus former industry executives
- Typical methods
- Expert calls, in-depth interviews, online surveys, advisory boards and competitive intelligence
- Research focus
- patient finding · centres of excellence · advocacy groups · pricing
- Geography
- 100+ Indian cities, metro and tier 2, plus global peer benchmarks
- Expert matching
- 24–48 hours from a confirmed brief
- Fieldwork window
- 5–10 business days for most interview and survey studies
- Core outputs
- Screened respondent profiles, recordings and transcripts, coded data tables and a rare diseases readout with implications
- Regulatory context
- Studies are designed with CDSCO, FDA and EMA requirements in mind, and run under the pharmaceutical market research codes.
Scope, sample and timings are confirmed in writing before fieldwork starts.
Why teams commission it
Decisions rare diseases research supports
Each brief starts from the decision it has to inform, so the readout answers the question your team is actually facing.
Where to compete
Which rare diseases segments, indications and accounts justify investment, and how patient finding changes that picture.
What to build
Which features, claims and configurations stakeholders genuinely value, pressure-tested against centres of excellence.
What it can be priced at
What buyers and payers will fund, the evidence they ask for first, and how advocacy groups shapes willingness to pay.
How to launch
Sequencing, channel and messaging choices, grounded in how pricing works in day-to-day practice.
Who to partner with
How potential partners, distributors and referral sources read your proposition in rare diseases.
Where the risk sits
Competitive moves, switching triggers and the objections most likely to stall rare diseases adoption.
Stakeholders
Who we reach in rare diseases
We recruit the people who make and influence the decision — not only the easiest audience to find. Every expert is screened for recency of practice and conflicts of interest.
Clinical and scientific
- Senior clinicians in private and public hospitals
- Clinical investigators and trial site staff
- Hospital and specialty pharmacists
- Clinical coordinators and technical staff
Rare Diseases commercial teams
- Brand, portfolio and marketing leads
- Market access, pricing and HEOR leads
- Business development and licensing leads
- Medical affairs and MSL teams
Buyers, payers and influencers
- Procurement and category managers
- Payer medical directors and HTA assessors
- Group purchasing and tender committees
- Patient support programme managers
How it runs
A rare diseases research programme, stage by stage
Senior researchers at our Pune, Maharashtra, India headquarters design, moderate and analyse every study.
- 01
Brief and research design
We turn your rare diseases question into a screener, discussion guide or questionnaire, and agree the decision the readout has to support.
Scoped in writing
- 02
Recruit and screen
We identify rare diseases stakeholders from our 5,000+ network, then screen for recency of practice, relevance and conflicts before anything is booked.
24–48 hours
- 03
Fieldwork
Expert calls, in-depth interviews or surveys run with senior moderation, covering patient finding and the rest of your question set.
5–10 business days
- 04
Analysis and readout
Findings are coded, triangulated across audiences and delivered as a decision-ready report, with a live debrief for your team.
Report and debrief
Compliance
Standards every rare diseases study runs under
Compliance is designed into the screener and the guide, not bolted on at the end.
Research codes
rare diseases guides follow EphMRA, BHBIA and Insights Association standards, including adverse event and off-label handling.
Regulatory framing
Studies are designed with CDSCO, FDA and EMA requirements in mind, and run under the pharmaceutical market research codes.
Data protection
Recruitment, transcripts and data files are handled under GDPR, HIPAA and India's DPDP Act, with pseudonymised outputs.
Conflict screening
Every expert is screened for employer restrictions, confidentiality obligations and conflicts of interest before a session is confirmed.
FAQs
Rare Diseases market research questions
What is rare diseases market research?+
rare diseases market research is primary research with the clinicians, buyers, payers and executives who shape the rare diseases market. HealthcareMarketResearch covers patient finding, centres of excellence, advocacy groups, pricing through expert calls, in-depth interviews, surveys and advisory boards.
Who do you interview for rare diseases studies?+
We recruit from a network of 5,000+ market researchers, KOLs and healthcare experts. For rare diseases that typically means practising specialists, hospital pharmacists, procurement and value analysis leads, payers and former industry executives, all screened for recency and conflicts.
How quickly can a rare diseases project start?+
Expert calls usually start within 24–48 hours of a confirmed brief. Surveys and qualitative studies typically go to field in 5–10 business days, depending on audience and sample size.
Which rare diseases questions can you answer?+
Hard-to-reach patient and specialist research for orphan drug developers. Common briefs cover patient finding, centres of excellence, advocacy groups, pricing, along with competitor positioning, pricing expectations and launch readiness.
Is your rare diseases research compliant?+
Yes. Studies follow EphMRA, BHBIA and Insights Association guidelines, with adverse event reporting and off-label rules written into every guide. Studies are designed with CDSCO, FDA and EMA requirements in mind, and run under the pharmaceutical market research codes.
Coverage
Where we run rare diseases research in India
Studies are designed and analysed at our Pune, Maharashtra, India headquarters, with recruitment and fieldwork across 100+ Indian cities — metro, tier 2 and tier 3.
All industries
Explore the other 24 healthcare segments
Grouped by the kind of organisation or therapy area you work in, so you can find the neighbouring page quickly.
Life sciences companies
Therapy areas
Care delivery, payers and technology
Have a healthcare question that needs real answers?
Brief us today and talk to a verified expert this week.